• U.S. stock markets opened the week higher
• President trump changes his rhetoric regarding lifting restrictions in April
• Johnson & Johnson (JNJ.US) will soon start testing for a coronavirus vaccine
US indices opened higher today in attempt to extend gains from last week after several companies announced progress in developing drug and vaccine for coronavirus. During the weekend President Trump dispelled all hopes for an early release from the lockdown policies on the U.S. economy by Easter. The current guidance on social distancing has been extended to the end of April.
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile appIn the opinion of Dr. Anthony Fauci, which is the White House medical adviser, the virus could kill up to 200,000 US citizens. At the moment US is the most affected country in the world with over 142.000 confirmed cases and almost 2500 deaths. Therefore further news regarding the spread of the pandemic will have the biggest impact on the markets, as investors try to assess whether announced fiscal and monetary stimulus will be enough to offset the economic impact of coronavirus outbreak.
S&P 500 (US500) – managed to defend key support level at 2505pts and is trying to recover Friday’s losses. However, market sentiment remains negative as investors seem to be concerned about the spread of the epidemic and the growing number of new cases. Therefore it should be assumed that unless positive news hits the markets, then the above mentioned resistance may be tested again. Source:xStation5
Johnson & Johnson (JNJ.US) is trading higher today after company announced that it has a leading candidate for a coronavirus vaccine in collaboration with the US Department of Health and Welfare. Clinical tests are likely to begin in September 2020 and the first batches of vaccine may be available early next year. The company has committed to providing a billion vaccines worldwide in response to an outbreak of coronavirus.
Johnson & Johnson (JNJ.US) is trading in upward correction move, based on positive news regarding potential coronavirus vaccine. Price broke above major resistance at $125.61. In case the current sentiment prevails J&J stock prices many move towards next resistance level at $136.35. Support can be found at $118.18. Source: xStation5
Papa John’s (PZZA.US) – investor advisory firm ISS advised that retired basketball superstar Shaquille O’Neal should not be re-elected to the board of the pizza chain, as he skipped too many board meetings. ISS believes that shareholders should vote against his re-election at the next annual meeting, according to a Bloomberg.
Papa John’s (PZZA.US) – share price bounced off the major resistance level at $54.95 which is additionally strengthen by 200 MA (marked in red) and may continue its downward movment towards support located at $38.00. Source:xStation5
Novartis (NVS) – advised that its malaria drug hydroxychloroquine is the drugmaker’s biggest hope against COVID-19.
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
